A61P 7 - Drugs for disorders of the blood or the extracellular fluid

Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065)
12/2004
12/08/2004	CN1178691C Medicine for clinical hemostasis and preparing method thereof
12/07/2004	US6828456 2-amino-2-alkyl-3 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors
12/07/2004	US6828440 Analgesics; side effect reduction
12/07/2004	US6828418 Stable bactericidal/permeability-increasing protein products and pharmaceutical compositions containing the same
12/07/2004	US6828341 Brain disorders; anticonvulsants; central nervous system disorders; psychological disorders
12/07/2004	US6828338 Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
12/07/2004	US6828327 Macroheterocylic compounds useful as kinase inhibitors
12/07/2004	US6828318 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission
12/07/2004	US6828312 Therapy of mammal susceptible to, suffering from, suspected of having or recovering from a disease impacted by tissue factor(TF), by administering TF blocking compound
12/07/2004	US6828307 Obtained by Depolymerization of a Fucan From Phaeophyceae
12/07/2004	US6828306 Charged lipid compositions and methods for their use
12/07/2004	US6827926 Administering a porphyrin compound that coordinates gallium in the central pyrrolic core, and irradiating porphyrin compound with energy at a wavelength capable of exciting the molecule to achieve the desired detection or therapeutic effect
12/07/2004	CA2208673C Composition for inhibiting intimal hyperplasia using pdgf antagonists and heparin
12/07/2004	CA2107516C Antithrombin iii preparation
12/02/2004	WO2004104004A2 Triaza-spiro compounds as nociceptin analogues and uses thereof
12/02/2004	WO2004103406A1 Therapeutic composition for disease accompanied by decrease or increase of platelet
12/02/2004	WO2004103397A1 Compositions comprising factor viii and factor ixa for treating haemophilia
12/02/2004	WO2004103264A2 Hemostatic antibacterial composition and products incorporating the same
12/02/2004	WO2004034993A3 Methods of preventing morbidity and mortality by perioperative administration of a blood clotting inhibitor
12/02/2004	WO2004026815A3 Phenol derivatives and their use as rotamase inhibitors
12/02/2004	WO2003064387A3 Substituted indoles as alpha-1 agonists
12/02/2004	WO2003011106A3 Internal image antibodies for optical imaging and therapy
12/02/2004	US20040244062 Use of protein inhibitors as antithrombotic agents
12/02/2004	US20040243226 Means and method for the treatment of coronary artery obstructions
12/02/2004	US20040243097 Antiproliferative drug and delivery device
12/02/2004	US20040242928 Reverse hydroxamic acid derivatives
12/02/2004	US20040242868 Controlling cytokines; antiinflammatory agents; rheumatic disoreders; skin disorders; respiratory system disorders; Alzheimer's disease; Parkinson's disease; Huntington"s disease ; amyotrophic lateral sclerosis
12/02/2004	US20040242692 4-(3-(2,6-Dimethoxybenzyloxy)phenyl)-4-oxobutyric acid or derivatives for treatment of insulin resistance syndrome, diabetes, cachexia, hyperlipidemia, fatty liver disease, obesity, atherosclerosis or arteriosclerosis
12/02/2004	US20040242687 Thrombus/thrombogenesis inhibitors
12/02/2004	US20040242675 Compositions useful for the treatment of pathologies responding to the activation of PPAR-gamma receptor
12/02/2004	US20040242660 Combinations of oxazolidinones with other active ingredients for the prophylaxis and/or treatment of thromboembolic disorders
12/02/2004	US20040242656 N-heterocyclicamide compounds; useful in the treatment of cardiovascular disorders, in particular, as an anticoagulant
12/02/2004	US20040242647 Use of organic compounds
12/02/2004	US20040242627 2-Iminoimidazole derivatives (1)
12/02/2004	US20040242617 Combination of selected opioids with muscarine antagonists for treating urinary incontinence
12/02/2004	US20040242595 Pyrimidine derivatives
12/02/2004	US20040242585 Acylsulfamide inhibitors of factor VIIa
12/02/2004	US20040242581 potent inhibitors of factor Xa which may have high bioavailability following oral administration
12/02/2004	US20040242567 alone or in combination with a diuretic agent; diabetic nephropathy
12/02/2004	US20040242564 1,2,3,4-tetrahydroisoquinolines derivatives
12/02/2004	US20040242547 Arylazo-substituted imidazole for the treatment of stress urinary incontinence
12/02/2004	US20040242480 Method for treating coumarin-induced hemorrhage
12/02/2004	US20040242455 which exerts potent and selective activated blood coagulation factor X inhibitory activity and is useful for prevention or treatment of disease associated therewith
12/02/2004	US20040241803 25 human secreted proteins
12/02/2004	US20040241228 Spirolaxine acts as active principle in association with all-trans retinoic acid for treatment of those pathologies responding to activation of PPAR gamma receptor, such as acute malignant haemopathies. and Type 2 insulin-resistant diabetes
12/02/2004	US20040241204 Sustained release pharmaceutical composition
12/02/2004	US20040241094 Oily paclitaxel composition and formulation for chemoembolization and preparation method thereof
12/02/2004	CA2532059A1 Triaza-spiro compounds as nociceptin analogues and uses thereof
12/02/2004	CA2524950A1 Methods for facilitating recovery of functions of endogenous or implanted or transplanted stem cells using high molecular weight hyaluronic acid
12/02/2004	CA2469528A1 Peptide and peptide mimetic derivatives having integrin inhibitor properties iii
12/01/2004	EP1482046A2 G-CSF analog compositions and methods
12/01/2004	EP1482045A2 G-CSF analog compositions and methods
12/01/2004	EP1482044A2 Multivariant IL-3 hematopoiesis fusion protein
12/01/2004	EP1481989A1 A-33 related antigens and their pharmacological uses
12/01/2004	EP1481976A1 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
12/01/2004	EP1481067A1 Expression cassette for persistence of expression of a gene of interest in muscle cells
12/01/2004	EP1480993A2 Desaturase genes, enzymes encoded thereby, and uses thereof
12/01/2004	EP1480973A1 1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases
12/01/2004	EP1480971A1 Isoquinoline derivatives
12/01/2004	EP1480962A1 5-phenylthiazole derivatives and use as pi3 kinase inhibitors
12/01/2004	EP1480959A1 Piperazine derivatives as anti-inflammatory agents
12/01/2004	EP1480948A1 Semicarbazide derivatives and their use as antithrombotics
12/01/2004	EP1480688A1 N-(5- 4-(4-methyl-piperazino-methyl)-benzoylamido)-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidine-amine coated stents
12/01/2004	EP1480659A1 Use of zeolithes for reducing the proportion of lactates and ammonium in human and animal organisms
12/01/2004	EP1480658A2 Methods of treating vascular disease
12/01/2004	EP1480652A1 Use of phospholipids in peritoneal dialysis
12/01/2004	EP1480628A1 Use of sodium/hydrogen exchange inhibitors for the treatment of thrombotic and inflammatory diseases
12/01/2004	EP1480598A2 Manipulation of cytokine levels using cd83 gene products
12/01/2004	EP1176975A4 Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
12/01/2004	EP1139784B1 Food-induced antisecretory proteins in egg yolk
12/01/2004	EP0977745B1 Thioaryl sulfonamide hydroxamic acid compounds
12/01/2004	CN1551914A FAD4, FAD5, FAD5-2 and FAD6, novel fatty acid desaturase family members and uses thereof
12/01/2004	CN1551779A Osteogenis oligopeptide as blood-formation stimulation articles
12/01/2004	CN1551769A Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
12/01/2004	CN1551728A Production of transduced hematopoietic progenitor cells
12/01/2004	CN1550504A Process of high purity albumin production
12/01/2004	CN1550502A Signal sequences for the production of Leu-hirudine via secretion by E. coli in a culture medium
12/01/2004	CN1550496A Acetylenic alpha-amino acid-based sulfamide hydroxamic acid TACE inhibitors
12/01/2004	CN1177865C Glycosaminoglycans derived from the K5 polysaccharide having high anticoagulant and antithrombotic activity and process for their preparation
12/01/2004	CN1177855C Carbohydrate derivatives
12/01/2004	CN1177823C Pesticides
12/01/2004	CN1177612C Composition for sustained release of non-aggregated erythropoietin
11/2004
11/30/2004	US6825355 For therapy of immunologic disorders such as transplant rejection, rheumatoid arthritis. multiple sclerosis, inflammatory bowel disease, lupus, graft vs. host disease
11/30/2004	US6825217 Heterocyclic amines such as 4-(3'-thienyl)-alpha, alpha, 1-trimethyl-4-piperidinemethanol and/or prodrugs, used as analgesics for prophylaxis of neuropathic pain
11/30/2004	US6825208 Selective inhibitors of serine protease enzymes, especially factor viia; modulation of the coagulation cascade.
11/30/2004	US6825197 Cyclic GMP-specific phosphodiesterase inhibitors
11/30/2004	US6825191 Benzodiazepine derivatives
11/30/2004	US6825185 Improving the cardiovascular profile of a cox-2 selective inhibitor by administering with 3-hydroxy-3- methylglutaryl coenzyme a, an antiplatelet agent, a thrombin inhibitor or a thromboxane inhibitor
11/30/2004	US6825008 Expressed ligand—vascular intercellular signalling molecule
11/30/2004	US6824978 Regulation of endogenous gene expression in cells using zinc finger proteins
11/30/2004	US6824790 Capsule, tablet with enteric, protective coatings; bioavailability
11/30/2004	CA2298245C Matrix controlled release device
11/25/2004	WO2004101611A2 Peptides that bind to the erythropoietin receptor
11/25/2004	WO2004101563A1 AZAINDOLE-DERIVATIVES AS FACTOR Xa INHIBITORS
11/25/2004	WO2004101556A1 INDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS
11/25/2004	WO2004101555A1 TRIAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS
11/25/2004	WO2004101554A1 New indole derivatives as factor xa inhibitors
11/25/2004	WO2004101553A1 BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS
11/25/2004	WO2004100975A1 TREATMENT OF HAEMORRHAGIC SHOCK USING COMPLEMENT 5a RECEPTOR INHIBITORS
11/25/2004	WO2004100972A1 Preventive and/or remedy for diseases accompanied by tissue destruction

1 ... 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 ... 671